BioXcel Therapeutics Inc [BTAI] stock is trading at $0.54, down -3.85%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The BTAI shares have gain 2.60% over the last week, with a monthly amount drifted -12.91%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
BioXcel Therapeutics Inc [NASDAQ: BTAI] stock has seen the most recent analyst activity on February 21, 2024, when UBS downgraded its rating to a Neutral and also revised its price target to $4 from $9. Previously, Mizuho downgraded its rating to Neutral on August 15, 2023, and dropped its price target to $4. On July 17, 2023, downgrade downgraded it’s rating to Neutral. Jefferies downgraded its rating to a Hold and increased its price target to $22 on March 10, 2023. Goldman upgraded its rating to a Neutral but $16 remained the price target by the analyst firm on December 01, 2022. Mizuho started tracking with a Buy rating for this stock on July 07, 2022, and assigned it a price target of $19. In a note dated April 06, 2022, BofA Securities reiterated an Buy rating on this stock but restated the target price of $80.
BioXcel Therapeutics Inc [BTAI] stock has fluctuated between $0.50 and $5.62 over the past year. Currently, Wall Street analysts expect the stock to reach $12 within the next 12 months. BioXcel Therapeutics Inc [NASDAQ: BTAI] shares were valued at $0.54 at the most recent close of the market. An investor can expect a potential return of 2122.22% based on the average BTAI price forecast.
Analyzing the BTAI fundamentals
BioXcel Therapeutics Inc [NASDAQ:BTAI] reported sales of 2.40M for the trailing twelve months, which represents a growth of 141.58%. Gross Profit Margin for this corporation currently stands at 0.33% with Operating Profit Margin at -44.95%, Pretax Profit Margin comes in at -44.87%, and Net Profit Margin reading is -44.87%. To continue investigating profitability, this company’s Return on Assets is posted at -1.65, Equity is 1.77 and Total Capital is -2.83. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-1.39.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.5229 points at the first support level, and at 0.5058 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.5706, and for the 2nd resistance point, it is at 0.6012.
Ratios To Look Out For
For context, BioXcel Therapeutics Inc’s Current Ratio is 2.35. In addition, the Quick Ratio stands at 2.25 and the Cash Ratio stands at 2.06. Considering the valuation of this stock, the price to sales ratio is 9.16.
Transactions by insiders
Recent insider trading involved Yocca Frank, Chief Scientific Officer, that happened on Sep 16 ’24 when 355.0 shares were sold. CEO and President, Mehta Vimal completed a deal on Sep 16 ’24 to sell 1982.0 shares. Meanwhile, Chief Financial Officer Steinhart Richard I sold 356.0 shares on Sep 16 ’24.
